Clinical trial / 2011
Daily supplementation with 80 or 120 mg soy hypocotyl isoflavones for 2 years demonstrated minimal health risks in postmenopausal women.
A 24-month trial evaluated the safety and clinical outcomes of daily supplementation with 80 or 120 mg aglycone equivalent soy hypocotyl isoflavones (plus calcium and vitamin D) versus placebo in 403 postmenopausal women. After 2 years, all clinical chemistry values remained within normal ranges, though blood urea nitrogen increased significantly at 2 years (P = 0.048) but not at 1 year (P = 0.343). Isoflavone supplementation did not alter blood lymphocyte or serum free thyroxine concentrations, nor did it cause significant differences in endometrial thickness or fibroids. Two serious adverse events occurred (one breast cancer and one estrogen receptor-negative endometrial cancer), which was below the expected population rate.
- Study type
- Multicenter, randomized, double-blind, placebo-controlled trial
- Who was studied
- 403 healthy postmenopausal women
- What was measured
- Clinical blood chemistry, well-woman exam (mammogram, Pap test), endometrial thickness, and fibroids
THE PAPER
Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women.
Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, Barnes S, Konzelmann KL, Fischer JG, Ellis KJ, Shypailo RJ, Fraley JK, Smith EO, Wong WW. Am J Clin Nutr, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.